Monte Rosa Therapeutics, Inc. (GLUE)
Company Info
| ISIN | US61225M1027 |
|---|---|
| CUSIP | 61225M102 |
| Sector | Healthcare |
| Industry | Biotechnology |
Highlights
| Market Cap | $363.33M |
|---|---|
| EPS (TTM) | -$2.22 |
| Total Revenue (TTM) | $14.51M |
| Gross Profit (TTM) | $6.87M |
| EBITDA (TTM) | -$133.62M |
| Year Range | $2.44 - $8.84 |
| Target Price | $15.83 |
| Short % | 9.12% |
| Short Ratio | 14.21 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Popular comparisons: GLUE vs. ^XMI
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Monte Rosa Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Monte Rosa Therapeutics, Inc. had a return of 5.31% year-to-date (YTD) and -1.49% in the last 12 months.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | 5.31% | 17.79% |
| 1 month | 22.93% | 0.18% |
| 6 months | -20.13% | 7.53% |
| 1 year | -1.49% | 26.42% |
| 5 years (annualized) | N/A | 13.48% |
| 10 years (annualized) | N/A | 10.85% |
Monthly Returns
The table below presents the monthly returns of GLUE, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -6.28% | 19.55% | 11.37% | -24.54% | -22.56% | -9.22% | 20.86% | 36.50% | 5.31% | ||||
| 2023 | -2.76% | -17.84% | 28.12% | -41.72% | 62.56% | -7.18% | 3.21% | -16.97% | -18.40% | -29.02% | -8.82% | 82.26% | -25.76% |
| 2022 | -38.00% | 13.27% | -2.23% | -22.25% | -28.99% | 24.94% | -6.20% | -12.68% | 3.16% | 12.61% | -7.83% | -10.26% | -62.73% |
| 2021 | 7.18% | 8.02% | 45.55% | -37.57% | 5.25% | -17.31% | 5.31% | -3.59% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of GLUE is 48, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Monte Rosa Therapeutics, Inc. (GLUE) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Monte Rosa Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Monte Rosa Therapeutics, Inc. was 94.08%, occurring on Oct 25, 2023. The portfolio has not yet recovered.
The current Monte Rosa Therapeutics, Inc. drawdown is 85.90%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -94.08% | Sep 7, 2021 | 538 | Oct 25, 2023 | — | — | — |
| -18.11% | Jul 1, 2021 | 8 | Jul 13, 2021 | 8 | Jul 23, 2021 | 16 |
| -10.95% | Jun 25, 2021 | 1 | Jun 25, 2021 | 3 | Jun 30, 2021 | 4 |
| -7.83% | Aug 27, 2021 | 3 | Aug 31, 2021 | 2 | Sep 2, 2021 | 5 |
| -4.7% | Aug 11, 2021 | 2 | Aug 12, 2021 | 2 | Aug 16, 2021 | 4 |
Volatility
Volatility Chart
The current Monte Rosa Therapeutics, Inc. volatility is 36.58%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Monte Rosa Therapeutics, Inc..
Loading data...
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
| Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
| Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |